Skip to content
Study details
Enrolling now

Enfortumab Vedotin and Radiation Therapy for Bladder Cancer

University of Texas Southwestern Medical Center
NCT IDNCT06394570ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1/2

Target enrollment

19

Study length

about 2.8 years

Ages

18+

Locations

1 site in TX

What this study is about

Researchers are testing the safety and effectiveness of enfortumab vedotin combined with radiation therapy as a treatment before surgery for some people with muscle-invasive bladder cancer. The trial will use different doses to find the safest and most effective dose.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Take Enfortumab vedotin

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

enfortumab vedotin

Endpoints

Primary: Maximum Tolerated Dose (MTD) Regimen, Pathologic Complete response rate at radical cystectomy

Secondary: Adverse Events

Body systems

Oncology